Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) caught the attention of Jim Cramer recently. The stock has been volatile, with fluctuations due to meme stock status. Cramer noted early morning buying activity driving the stock up. However, he emphasized the need for a proof of concept before investing.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotech company specializing in drug discovery using automation and AI. Despite its potential, Cramer expressed skepticism due to the stock’s lackluster performance and the necessity for a proof of concept. The involvement of NVIDIA was mentioned, but Cramer remains cautious about investing in RXRX.

For investors seeking AI stocks, alternatives with higher growth potential and lower risk exist compared to RXRX. A report highlights an undervalued AI stock poised to benefit from Trump-era tariffs and onshoring trends. While RXRX may have potential, exploring other AI investment opportunities may offer better prospects.

For more stock investment insights, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey. This article does not contain any disclosures and was originally published on Insider Monkey.

Read more at Yahoo Finance: “Now, It’s a Meme Stock”